1 / 35

Strategy 2: Make the tissue more resilient to poor plumbing.

Strategy 2: Make the tissue more resilient to poor plumbing. Pros: Likely a pharmacological treatment Can be administered more quickly by 1 st response team Can extend therapeutic time window. May be of benefit to a large number of people. Cons: - Does not exist. How to treat stroke.

agough
Download Presentation

Strategy 2: Make the tissue more resilient to poor plumbing.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Strategy 2: Make the tissue more resilient to poor plumbing. • Pros: • Likely a pharmacological treatment • Can be administered more quickly by 1st response team • Can extend therapeutic time window. • May be of benefit to a large number of people. • Cons: • - Does not exist.

  2. How to treat stroke • Prevent excitotoxicity • Block excitotoxicity • Block downstream consequences of excitotoxicity • Treat non-excitotoxic mechanisms. • Treat white matter damage AND Maybe, just maybe, it’ll work…

  3. Prevent excitotoxicity • Prevent glutamate release • Block action potentials • Block neurotransmitter release

  4. Blocking action potentials • Na Channel Blockers • Potassium channel openers Advantages: Reduce need for energy (ATP), reduce synaptic glutamate release. Disadvantages: “Shut the patient down”, do not prevent non-synaptic glutamate release, systemic toxicity (cardiovascular).

  5. Blocking action potentials • Na Channel Blockers • Potassium channel openers Na channel blockers currently not in use. Clinical trials have shown no utility. Quaternary local anesthetics may be of utility, however currently experimental K+ channel openers have found utility in chronic spinal cord injury. Phase III trials ongoing for stroke treatment.

  6. Na channel blocker

  7. Potassium channel agonist

  8. Blocking NT release: Block presynaptic calcium entry SNX-111

  9. Presynaptic calcium channel blocker

  10. Blocking NT release: • Buffer presynaptic calcium ions • Prevents the rise of calcium concentrations to levels that cause neurotransmitter release • Experimental. • Interfere with vesicle fusion/docking/release • Tetanus toxin • Botulinum toxin Obviously not an immediate solution.

  11. Blocking NT release: Hypothermia. First used in neuorlogical diseases by Dr. Temple Fay, in the mid-late 1930’s

  12. Hypothermia

  13. Blocking Excitotoxicity: Agents that block postsynaptic receptors. General anesthetics are considered by some to be neuroprotective. Inhalational anesthetics may confer protection during neurosurgery (controversial).

  14. Blocking Excitotoxicity: Most commonly used are the IV anesthetics Barbiturates (activate GABA), propofol (activates GABA, blocks NMDA), ketamine (blocks NMDA). Barbiturates and propofol commonly used in neurosurgery for brain protection.

  15. Blocking excitotoxicity: • Blockers of • Postsynaptic Ca channels • NMDA receptor antagonists • AMPA/kainate receptor antagonists • GABA agonists

  16. Calcium channel blocker

  17. NMDA antagonist

  18. AMPA antagonist

  19. GABA agonist

  20. Prevent Consequences of Glutamate Receptor Activation Free radical scavengers Nitric Oxide Synthase antagonists Calpain Inhibitors Inhibitors of other intracellular enzymes (protein kinases, phosphatases) Calcium buffers

  21. NO and ROS antagonism

  22. Free radical scavenger:

  23. NOS antagonists

  24. Partial list of stroke drugs so far

  25. Complete list of effective drugs so far: tPA Pro-Urokinase Hypothemia

  26. Back to our patient • Operated under hypothermic circulatory arrest. • Placed on cardiac bypass • Temperature dropped to 15C • Pump turned off: • EEG flat, BP = 0

  27. Post-Op Pre-Op:

  28. Glia

  29. Glia Astrocytes Microglia Oligodendroglia Schwann cells

  30. Glia There are a few ways in which glia cells are different from neurons: 1. Neurons have TWO "processes" called axons and dendrites....glial cells only have ONE. 2. Neurons CAN generate action potentials...glial cells CANNOT. However, glial cells do have a resting potential. 3. Neurons HAVE synapses that use neurotransmitters...glial cells do NOT have chemical synapses. 4. Neurons do not continue to divide...glial cells DO continue to divide. 5. There are many MORE (10-50 times more) glial cells in the brain compared to the number of neurons.

  31. Glial Cells More numerous than neurons Have many different functions Nutritive Electrical Insulators Scavengers (immunological role) K+ buffers Cell guidance Tight junctions (Blood-Brain Barrier)

  32. Recently, glial cells have been shown to be much more “active” • Glia communicate to each other via gap junctions • Glia communcate with neurons via gap junctions • Gap junctions permit the diffusion of calcium ions and IP3. The latter causes calcium release from internal stores. • Glial communication may underlie a number of pathological conditions

  33. Glial activity may underlie pathological conditions: • “Spreading depression” – propagating waves of negative DC potential that are believed to spread the ischemic penumbra • Migraine (?)

  34. Calcium waves in astrocytes

  35. Glia recently recognized as targets of excitotoxicity Oligodendroglial cells express AMPA subtype of glutamate receptors. Oligodendroglia are the white matter cell most susceptible to excitotoxicity in anoxic injury. From: Li S, Mealing GA, Morley P, Stys PK J Neurosci 1999 Jul 15;19(14):RC16

More Related